T-DM1 improved overall survival for heavily pretreated patients with HER2-pos breast cancer

Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with trastuzumab emtansine (T-DM1 [Kadcyla]) compared with those who received treatment of physician's choice, according to results from the phase III TH3RESA clinical trial.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1P1JcS6